CAMBRIDGE, Mass.– At the ISPOR Montreal 2025 Conference in May, CapeStart, Inc. announced a major upgrade to MadeAi™, its award-winning generative AI platform designed to streamline and accelerate scientific research and regulatory processes for life sciences teams.
The new release introduces groundbreaking capabilities to the platform’s flagship solution, MadeAi-LR, promising to halve literature review time while delivering 90% accuracy.
CapeStart’s enhancements to MadeAi-LR include AI-aided and AI-as-Reviewer modes, advanced extraction features, built-in quality appraisal tools, and expanded screening models—innovations aimed at helping pharmaceutical, biotech, and medtech organizations manage increasingly complex evidence synthesis workflows.
“Our latest release offers enhancements that allow the GenAI to support more dynamic aspects of literature review research—including AI as Reviewer, Arm-level Extraction, and Quality Appraisals—so teams can scale faster and focus on what matters most: advancing science,” said Gaugarin Oliver, founder and CEO of CapeStart.
AI-Aided Review & AI as Reviewer: The platform now supports dual modes for title/abstract and full-text screening. In AI-aided mode, suggestions from the AI assist two blinded human reviewers. In AI as Reviewer mode, the AI works alongside a human reviewer, effectively replacing a second reviewer and significantly reducing manual workload.
Customizable Screening Criteria: More than a dozen standard criteria, including PICOS, are now available, along with support for user-defined criteria—providing greater flexibility for unique or novel project requirements.
Summary- and Arm-Level Extraction: Summary-level extraction gives users a high-level synthesis of study information, while Arm-level extraction delivers detailed, group-specific outcomes with traceable sources for quick validation and editing.
AI Agent-Enhanced Data Extraction: New AI tools extract information from diverse formats—including text, tables, graphs, and figures—enabling comprehensive data capture from complex clinical literature.
Integrated Quality Appraisal: Users can now assess the risk of bias directly within the MadeAi workflow, complete with visual summaries such as charts and tables for fast, data-driven decision-making.
Developed in collaboration with top 15 global pharmaceutical companies, MadeAi-LR offers a centralized, end-to-end literature review environment that ensures sourcing transparency, reproducibility, and regulatory alignment. Teams using the platform report dramatically faster turnaround times for systematic literature reviews (SLRs), clinical evidence reports (CERs), and meta-analyses.
CapeStart reports that many of its clients are achieving immediate ROI, enabling leaner research teams to tackle more literature reviews at scale, while improving the quality and reliability of their outputs.
Since its launch in late 2024, MadeAi has earned widespread industry recognition. The platform has received multiple honors, including:
- A Stevie® Award for AI/ML Innovation in Healthcare
- Inclusion in PM360’s 2024 Innovators list for Generative AI
- Winner of the 2025 Artificial Intelligence Excellence Awards, presented by the Business Intelligence Group.
